Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 2 L ESCC
  • 1 L GC/GEJC
  • 1L NSQ NSCLC
  • 1L SQ NSCLC
  • 2L NSCLC

This site is inteded for health care proffesional.

NSCLC

RATIONALE 303: A randomized phase 3 trial in nearly 805 patients with 2L, locally advanced or metastatic  NSCLC (Squamous or Non-squamous)

Key Efficacy Outcome: mPFS

3.7x more patients treated with Etapidi versus docetaxel were progression-free at 12 months1

Key Efficacy Outcome: ORR & mDOR

Etapidi improved the overall response rate and disease control rate versus docetaxel 1,2

Explore Clinical Safety

Access detailed safety and tolerability information to support treatment considerations in 2L NSCLC.

View safety in 2L NSCLC

Tislelizumab Versus .Docetaxel in Patients with Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Reference: 1. SUPPLEMENTAL APPENDIX RATIONALE-303 : Zhou, Caicun et al. Journal of Thoracic Oncology, 2023, Volume 18, Issue 1, 93 – 106.